| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Trial completed |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Enrollment reduced: 200 -> 50 participants |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Primary completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-06-12 | NCT07567846 A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in… |
Recruitment opened |
| 2026-06-12 | NCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam… |
date change Primary completion moved earlier: 2029-02-27 -> 2026-10-28 |
| 2026-06-12 | NCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam… |
date change Completion moved earlier: 2029-02-27 -> 2026-10-28 |
| 2026-06-11 | NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People… |
Trial sites expanded: 4 -> 55 locations |
| 2026-06-10 | NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus… |
Trial sites expanded: 240 -> 251 locations |
| 2026-06-10 | NCT07368998 To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With… |
Trial sites expanded: 19 -> 26 locations |
| 2026-06-10 | NCT06176352 A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal… |
Trial completed |
| 2026-06-10 | NCT07448038 A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics… |
Trial sites expanded: 6 -> 11 locations |
| 2026-06-09 | NCT06534983 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus… |
Primary endpoint(s) modified |
| 2026-06-09 | NCT06534983 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus… |
Enrollment reduced: 362 -> 62 participants |
| 2026-06-09 | NCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-09 | NCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… |
Trial sites reduced: 82 -> 54 locations |
| 2026-06-09 | NCT06819891 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart… |
Trial sites expanded: 173 -> 178 locations |
| 2026-06-09 | NCT06693908 A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate… |
date change Primary completion pushed: 2026-06-09 -> 2026-07-09 |
| 2026-06-09 | NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics… |
Enrollment reduced: 152 -> 120 participants |
| 2026-06-09 | NCT05503264 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics… |
date change Completion moved earlier: 2029-12-14 -> 2028-12-14 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07629583 To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus… | Phase 1 | Not Yet Recruiting |
| 2026-06-04 | NCT07626515 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07620392 An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants… | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07617337 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | Phase 1 | Not Yet Recruiting |
| 2026-05-27 | NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… | Phase 4 | Not Yet Recruiting |
| 2026-05-20 | NCT07598396 A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With… | Phase 2 | Recruiting |
| 2026-05-15 | NCT07589686 A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity… | Phase 2 | Not Yet Recruiting |
| 2026-05-14 | NCT07588100 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05861986 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… | Muscular Atrophy, Spinal | Recruiting |
| NCT04853251 | A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… | Neovascular Age-related Macular Degeneration | Recruiting |
| NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Relapsing Multiple Sclerosis | Recruiting |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies | Breast Cancer | Recruiting |
| NCT05861999 | A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… | Muscular Atrophy, Spinal | Recruiting |
| NCT05232929 | Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) | Spinal Muscular Atrophy | Active, Not Recruiting |
| NCT05181618 | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… | Severe Hemophilia A | Active, Not Recruiting |
| NCT06795048 | A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… | Neovascular Age-related Macular Degeneration (nAMD) | Active, Not Recruiting |
| NCT07025811 | A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants… | Dry Eye Disease | Active, Not Recruiting |
| NCT05224102 | A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… | Diabetic Macular Edema | Active, Not Recruiting |
| NCT07609719 | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… | Multiple Sclerosis | Not Yet Recruiting |
| Phase 3 | |||
| NCT06675955 | An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and… | Multiple Sclerosis | Recruiting |
| NCT06094010 | A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants… | Influenza | Recruiting |
| NCT05797610 | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants… | Primary IgA Nephropathy | Recruiting |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… | Cancer | Recruiting |
| NCT07298421 | A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for… | Moderately to Severely Active Crohns Disease | Recruiting |
| NCT06998524 | A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von… | Von Willebrand Disease, Type 3 | Recruiting |
| NCT07158242 | A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121)… | Moderately to Severely Active Ulcerative Colitis | Recruiting |
| NCT06847542 | A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD | Neovascular Age-related Macular Degeneration | Recruiting |
| NCT07351058 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… | Obesity or Overweight | Recruiting |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Multiple Myeloma | Recruiting |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… | Metastatic Breast Cancer | Recruiting |
| NCT07351045 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With… | Obesity or Overweight | Recruiting |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic… | Chronic Obstructive Pulmonary Disease | Recruiting |
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… | Lymphoma | Recruiting |